Firm
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Matthew Grady of Wolf Greenfield says AI presents an opportunity in patent practice for stronger collaboration between in-house and outside counsel
Discussion hosted by Bird & Bird partners also hears that UK courts’ desire to determine FRAND rates could see the jurisdiction penalised in a similar way to China
Sponsored
Sponsored
-
Sponsored by Tilleke & GibbinsKhin Yadanar Htay and Khin Myo Myo Aye of Tilleke & Gibbins summarise Myanmar’s new Geographical Indication Rules, covering application procedures, local representation requirements, and GI logo authorisation for domestic and international applicants -
Sponsored by Tilleke & GibbinsProactive measures are needed to counteract opportunistic bad-faith actors, say Diep Thi Bich Le and Hang Thi Thanh Phan of T&G Law Firm LLC (TGVN), the local associate of Tilleke & Gibbins
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law explains how a ruling has rejected attempts to limit protection to initially approved drug indications
-
Sponsored by Saint Island International Patent & Law OfficesThe District Court of New Taipei City’s findings on copyright infringement through bulk reproduction highlight key lessons on fair use and data scraping, says Steven Liao of Saint Island International Patent & Law Offices
-
Sponsored by Spoor & FisherThe introduction of a formal registration system under the Trademark Act modernises brand protection in the Maldives and signals a historic shift for rights holders, says Matthew Costard of Spoor & Fisher Jersey
-
Sponsored by Patrinos & KilimirisMaria Kilimiris of Patrinos & Kilimiris explains how an interim ruling concerning the likelihood of confusion between Fenistil and Knistil highlights how pharmaceutical trademarks and product get-up are assessed under EU and national law
